And having both treatments managed under one experienced clinician helps keep your care joined-up, consistent, and personalised.
Clinical trials show semaglutide users report decreased cravings for high-calorie foods within 24 weeks of starting therapy
The Lancet Global Health , 10 (3), e326-e328
This FDA-approved medication is notable for its dual action on GLP-1 and GIP receptors, making it highly effective in reducing appetite and enhancing metabolism
Common side effects reported in clinical trials and post-market surveillance include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite
Cardiometabolic parameters are measurements of the health of the heart, blood vessels, and metabolic system